| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Animal: RNA Viruses |
Department of Viral Therapeutics, Virology Division, United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, Frederick, MD 21702-5011, USA1
Author for correspondence: Mike Bray. Fax +1 301 619 2290. e-mail mike.bray{at}det.amedd.army.mil
Adult immunocompetent mice inoculated with Ebola (EBO) or Marburg (MBG) virus do not become ill. A suckling-mouse-passaged variant of EBO Zaire ’76 (‘mouse-adapted EBO-Z’) causes rapidly lethal infection in adult mice after intraperitoneal (i.p.) inoculation, but does not cause apparent disease when inoculated subcutaneously (s.c.). A series of experiments showed that both forms of resistance to infection are mediated by the Type I interferon response. Mice lacking the cell-surface IFN-
/
receptor died within a week after inoculation of EBO-Z ’76, EBO Sudan, MBG Musoke or MBG Ravn, or after s.c. challenge with mouse-adapted EBO-Z. EBO Reston and EBO Ivory Coast did not cause illness, but immunized the mice against subsequent challenge with mouse-adapted EBO-Z. Normal adult mice treated with antibodies against murine IFN-/ could also be lethally infected with i.p.-inoculated EBO-Z ’76 or EBO Sudan and with s.c.-inoculated mouse-adapted EBO-Z. Severe combined immunodeficient (SCID) mice became ill 3–4 weeks after inoculation with EBO-Z ’76, EBO Sudan or MBG Ravn, but not the other viruses. Treatment with anti-IFN-/ antibodies markedly accelerated the course of EBO-Z ’76 infection. Antibody treatment blocked the effect of a potent antiviral drug, 3-deazaneplanocin A, indicating that successful filovirus therapy may require the active participation of the Type I IFN response. Mice lacking an IFN-/ response resemble primates in their susceptibility to rapidly progressive, overwhelming filovirus infection. The outcome of filovirus transfer between animal species appears to be determined by interactions between the virus and the innate immune response.
This article has been cited by other articles:
|
|
 |
|
  A. Okumura, P. M. Pitha, and R. N. Harty ISG15 inhibits Ebola VP40 VLP budding in an L-domain-dependent manner by blocking Nedd4 ligase activity PNAS, March 11, 2008; 105(10): 3974 - 3979. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 St. P. Reid, C. Valmas, O. Martinez, F. M. Sanchez, and C. F. Basler Ebola Virus VP24 Proteins Inhibit the Interaction of NPI-1 Subfamily Karyopherin {alpha} Proteins with Activated STAT1 J. Virol., December 15, 2007; 81(24): 13469 - 13477. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Fragkoudis, L. Breakwell, C. McKimmie, A. Boyd, G. Barry, A. Kohl, A. Merits, and J. K. Fazakerley The type I interferon system protects mice from Semliki Forest virus by preventing widespread virus dissemination in extraneural tissues, but does not mediate the restricted replication of avirulent virus in central nervous system neurons J. Gen. Virol., December 1, 2007; 88(12): 3373 - 3384. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Pereira, M Todorova, X Cai, C. Makaroff, R. Emery, and B. Moffatt Methyl recycling activities are co-ordinately regulated during plant development J. Exp. Bot., March 1, 2007; 58(5): 1083 - 1098. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Dowling, E. Thompson, C. Badger, J. L. Mellquist, A. R. Garrison, J. M. Smith, J. Paragas, R. J. Hogan, and C. Schmaljohn Influences of Glycosylation on Antigenicity, Immunogenicity, and Protective Efficacy of Ebola Virus GP DNA Vaccines J. Virol., February 15, 2007; 81(4): 1821 - 1837. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Feng, M. Cerveny, Z. Yan, and B. He The VP35 Protein of Ebola Virus Inhibits the Antiviral Effect Mediated by Double-Stranded RNA-Dependent Protein Kinase PKR J. Virol., January 1, 2007; 81(1): 182 - 192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Krishnamurthy, T. Takimoto, R. A. Scroggs, and A. Portner Differentially regulated interferon response determines the outcome of newcastle disease virus infection in normal and tumor cell lines. J. Virol., June 1, 2006; 80(11): 5145 - 5155. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
St. P. Reid, L. W. Leung, A. L. Hartman, O. Martinez, M. L. Shaw, C. Carbonnelle, V. E. Volchkov, S. T. Nichol, and C. F. Basler Ebola Virus VP24 Binds Karyopherin {alpha}1 and Blocks STAT1 Nuclear Accumulation. J. Virol., June 1, 2006; 80(11): 5156 - 5167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Kash, E. Muhlberger, V. Carter, M. Grosch, O. Perwitasari, S. C. Proll, M. J. Thomas, F. Weber, H.-D. Klenk, and M. G. Katze Global Suppression of the Host Antiviral Response by Ebola- and Marburgviruses: Increased Antagonism of the Type I Interferon Response Is Associated with Enhanced Virulence J. Virol., March 15, 2006; 80(6): 3009 - 3020. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. G. Olinger, M. A. Bailey, J. M. Dye, R. Bakken, A. Kuehne, J. Kondig, J. Wilson, R. J. Hogan, and M. K. Hart Protective Cytotoxic T-Cell Responses Induced by Venezuelan Equine Encephalitis Virus Replicons Expressing Ebola Virus Proteins J. Virol., November 15, 2005; 79(22): 14189 - 14196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Shinozaki, O. Ebert, A. Suriawinata, S. N. Thung, and S. L. C. Woo Prophylactic Alpha Interferon Treatment Increases the Therapeutic Index of Oncolytic Vesicular Stomatitis Virus Virotherapy for Advanced Hepatocellular Carcinoma in Immune-Competent Rats J. Virol., November 1, 2005; 79(21): 13705 - 13713. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Ji, G. G. Olinger, S. Aris, Y. Chen, H. Gewurz, and G. T. Spear Mannose-binding lectin binds to Ebola and Marburg envelope glycoproteins, resulting in blocking of virus interaction with DC-SIGN and complement-mediated virus neutralization J. Gen. Virol., September 1, 2005; 86(9): 2535 - 2542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gupta, S. Mahanty, P. Greer, J. S. Towner, W.-J. Shieh, S. R. Zaki, R. Ahmed, and P. E. Rollin Persistent Infection with Ebola Virus under Conditions of Partial Immunity J. Virol., January 15, 2004; 78(2): 958 - 967. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. F. Basler, A. Mikulasova, L. Martinez-Sobrido, J. Paragas, E. Muhlberger, M. Bray, H.-D. Klenk, P. Palese, and A. Garcia-Sastre The Ebola Virus VP35 Protein Inhibits Activation of Interferon Regulatory Factor 3 J. Virol., July 15, 2003; 77(14): 7945 - 7956. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rao, M. Bray, C. R. Alving, P. Jahrling, and G. R. Matyas Induction of Immune Responses in Mice and Monkeys to Ebola Virus after Immunization with Liposome-Encapsulated Irradiated Ebola Virus: Protection in Mice Requires CD4+ T Cells J. Virol., August 12, 2002; 76(18): 9176 - 9185. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
